Sp467

BUILDING YOUR NET WORTH

Date
May 19, 2024

Presenter


Tracks

Related Products

Thumbnail for UTILITY AND UTILIZATION OF TRANSABDOMINAL ULTRASOUND IN PEDIATRIC PATIENTS WITH ACUTE RECURRENT OR CHRONIC PANCREATITIS
UTILITY AND UTILIZATION OF TRANSABDOMINAL ULTRASOUND IN PEDIATRIC PATIENTS WITH ACUTE RECURRENT OR CHRONIC PANCREATITIS
BACKGROUND: Transabdominal ultrasound (TAUS) is frequently utilized in pediatric acute pancreatitis for its ready availability, low cost, and lack of ionizing radiation or need for anesthesia…
Thumbnail for CB1 RECEPTOR LOCALIZATION WITHIN THE AFFERENT SPLANCHNIC NEURONS AND ITS IMPACT ON FEEDING BEHAVIOR AND ENERGY EXPENDITURE
CB1 RECEPTOR LOCALIZATION WITHIN THE AFFERENT SPLANCHNIC NEURONS AND ITS IMPACT ON FEEDING BEHAVIOR AND ENERGY EXPENDITURE
BACKGROUND: Our previous research has showed that increased sympathetic nervous activity and decreased cannabinoid receptor 1 (CB1) were associated with increased energy expenditure and weight loss following Roux-en-Y gastric bypass (RYGB) in mice…
Thumbnail for PERSISTENCE OF SPLANCHNIC GENE SIGNATURE DEFINES A TUMOR-RESTRAINING FIBROBLAST SUBTYPE IN PANCREATIC CANCER
PERSISTENCE OF SPLANCHNIC GENE SIGNATURE DEFINES A TUMOR-RESTRAINING FIBROBLAST SUBTYPE IN PANCREATIC CANCER
The pancreas is composed of the epithelial and mesenchymal cells. Interaction between the two lineages guides proper formation of the pancreas and modulates progression of pancreatic diseases such as cancer…
Thumbnail for SURVODUTIDE REDUCES LIVER FAT CONTENT, TRANSAMINASES, AND FIBROSIS MARKERS WITH GOOD SAFETY PROFILE IN PEOPLE WITH METABOLIC DYSFUNCTION-ASSOCIATED STEATOHEPATITIS (MASH): AN INTERIM ANALYSIS OF A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2 TRIAL
SURVODUTIDE REDUCES LIVER FAT CONTENT, TRANSAMINASES, AND FIBROSIS MARKERS WITH GOOD SAFETY PROFILE IN PEOPLE WITH METABOLIC DYSFUNCTION-ASSOCIATED STEATOHEPATITIS (MASH): AN INTERIM ANALYSIS OF A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2 TRIAL
BACKGROUND: Survodutide is a novel glucagon receptor/glucagon-like peptide-1 receptor dual agonist under investigation for treatment in advanced liver disease associated with metabolic dysfunction-associated steatohepatitis (MASH), the most severe form of metabolic dysfunction-associated steatotic…